← Back to All US Stocks

NewcelX Ltd. (NCEL) Fundamental Analysis & AI Grade 2026

NCEL Nasdaq Pharmaceutical Preparations V8 CIK: 0001783036
Recently Updated • Analysis: Jul 13, 2026 • SEC Data: 2026-07-13

NewcelX Ltd. (NCEL) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

NCEL Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

NCEL vs Healthcare Sector: How NewcelX Ltd. Compares

How NewcelX Ltd. compares to Healthcare sector averages

Net Margin
NCEL 0.0%
vs
Sector Avg 12.0%
NCEL Sector
ROE
NCEL 0.0%
vs
Sector Avg 15.0%
NCEL Sector
Current Ratio
NCEL 0.0x
vs
Sector Avg 2.0x
NCEL Sector
Debt/Equity
NCEL 0.0x
vs
Sector Avg 0.6x
NCEL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is NewcelX Ltd. Stock Overvalued? NCEL Valuation Analysis 2026

Based on fundamental analysis, NewcelX Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

NewcelX Ltd. Balance Sheet: NCEL Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

NCEL Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

NCEL SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for NewcelX Ltd. (CIK: 0001783036)

📋 Recent SEC Filings

Date Form Document Action
Apr 29, 2026 4 xslF345X06/ownership.xml View →
Apr 29, 2026 4 xslF345X06/ownership.xml View →
Nov 14, 2024 SC 13G armistice-nlsp093024.htm View →
Oct 15, 2024 SC 13G ea0217643-13galpha_nlsphar.htm View →
Mar 27, 2024 SC 13G sch13g.htm View →

Frequently Asked Questions about NCEL

What is the AI rating for NCEL?

NewcelX Ltd. (NCEL) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are NCEL's key strengths?

Claude: Analysis in progress.

What are the risks of investing in NCEL?

Claude: Analysis in progress.

What is NCEL's revenue and growth?

NewcelX Ltd. reported revenue of N/A.

Does NCEL pay dividends?

NewcelX Ltd. does not currently pay dividends.

Where can I find NCEL SEC filings?

Official SEC filings for NewcelX Ltd. (CIK: 0001783036) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is NCEL's EPS?

NewcelX Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is NCEL's fundamental grade?

Based on our AI fundamental analysis in July 2026, NewcelX Ltd. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is NCEL stock overvalued or undervalued?

Valuation metrics for NCEL: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is NCEL's AI grade for 2026?

Our dual AI analysis gives NewcelX Ltd. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is NCEL's free cash flow?

NewcelX Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.

How does NCEL compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% CRDO 87% AVGO 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Jul 13, 2026 | Data as of: 2026-07-13 | Powered by Claude AI